Literature DB >> 27153352

The role of PRDMs in cancer: one family, two sides.

Slim Mzoughi1, Ying Xim Tan2, Diana Low2, Ernesto Guccione3.   

Abstract

The PRDM family of proteins share a unique structure, with an N-terminal PR domain, which has a potential methyltransferase activity, followed by a distinct number of zinc fingers at the C-terminus, potentially mediating protein-protein, protein-RNA or protein-DNA interactions. Interestingly, despite no comprehensive functional data, all family members have been associated with deletions, mutations, epigenetic silencing or overexpression, in multiple cancer types. The intriguing observation is that different isoforms exist for almost all PRDM family members. These isoforms are not only differentially regulated, but play opposite roles in cancer, in what has been termed 'Yin and Yang' regulation, typical of this class of epigenetic regulators. Collectively, these findings set the stage for future intervention, by targeting directly their intrinsic catalytic activities, or indirectly, pathways that differentially regulate tumor suppressor/oncogenic isoform-expression.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27153352     DOI: 10.1016/j.gde.2016.03.009

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  35 in total

Review 1.  Off to a Bad Start: Cancer Initiation by Pluripotency Regulator PRDM14.

Authors:  Lauren J Tracey; Monica J Justice
Journal:  Trends Genet       Date:  2019-05-23       Impact factor: 11.639

2.  Direct interaction between the PRDM3 and PRDM16 tumor suppressors and the NuRD chromatin remodeling complex.

Authors:  Danton Ivanochko; Levon Halabelian; Elizabeth Henderson; Pavel Savitsky; Harshika Jain; Edyta Marcon; Shili Duan; Ashley Hutchinson; Alma Seitova; Dalia Barsyte-Lovejoy; Panagis Filippakopoulos; Jack Greenblatt; Evelyne Lima-Fernandes; Cheryl H Arrowsmith
Journal:  Nucleic Acids Res       Date:  2019-02-20       Impact factor: 16.971

3.  PRDM1 controls the sequential activation of neural, neural crest and sensory progenitor determinants.

Authors:  Ravindra S Prajapati; Mark Hintze; Andrea Streit
Journal:  Development       Date:  2019-12-16       Impact factor: 6.868

4.  Functional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors.

Authors:  Isabel Tegeder; Katharina Thiel; Serap Erkek; Pascal D Johann; Johannes Berlandi; Venu Thatikonda; Michael C Frühwald; Marcel Kool; Astrid Jeibmann; Martin Hasselblatt
Journal:  J Neurooncol       Date:  2018-11-16       Impact factor: 4.130

5.  Loss of prdm1a accelerates melanoma onset and progression.

Authors:  Ritsuko Iwanaga; Brittany T Truong; Jessica Y Hsu; Karoline A Lambert; Rajesh Vyas; David Orlicky; Yiqun G Shellman; Aik-Choon Tan; Craig Ceol; Kristin Bruk Artinger
Journal:  Mol Carcinog       Date:  2020-06-20       Impact factor: 4.784

6.  PRDM16 isoforms differentially regulate normal and leukemic hematopoiesis and inflammatory gene signature.

Authors:  David J Corrigan; Larry L Luchsinger; Mariana Justino de Almeida; Linda J Williams; Alexandros Strikoudis; Hans-Willem Snoeck
Journal:  J Clin Invest       Date:  2018-07-23       Impact factor: 14.808

7.  MiR-223-3p promotes the proliferation, invasion and migration of colon cancer cells by negative regulating PRDM1.

Authors:  Bao Chai; Yarong Guo; Xiangli Cui; Jinchun Liu; Yuhong Suo; Zhangfeng Dou; Ning Li
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

8.  PRDM15 safeguards naive pluripotency by transcriptionally regulating WNT and MAPK-ERK signaling.

Authors:  Slim Mzoughi; Jingxian Zhang; Delphine Hequet; Shun Xie Teo; Haitong Fang; Qiao Rui Xing; Marco Bezzi; Michelle Kay Yi Seah; Sheena L M Ong; Eun Myoung Shin; Heike Wollmann; Esther S M Wong; Muthafar Al-Haddawi; Colin L Stewart; Vinay Tergaonkar; Yuin-Han Loh; N Ray Dunn; Daniel M Messerschmidt; Ernesto Guccione
Journal:  Nat Genet       Date:  2017-07-24       Impact factor: 38.330

Review 9.  Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease.

Authors:  Kamakoti P Bhat; H Ümit Kaniskan; Jian Jin; Or Gozani
Journal:  Nat Rev Drug Discov       Date:  2021-01-19       Impact factor: 84.694

Review 10.  Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?

Authors:  Ewa M Michalak; Jane E Visvader
Journal:  Mol Oncol       Date:  2016-09-23       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.